Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Shares Issued (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Shares Issued for 8 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 729.74% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$5.3 million, a 175.28% decrease, with the full-year FY2024 number at $143000.0, changed N/A from a year prior.
  • Shares Issued was $1.2 million for Q3 2025 at Rein Therapeutics, up from -$345000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $55.6 million in Q1 2021 to a low of -$55.5 million in Q4 2021.
  • A 3-year average of $201333.3 and a median of -$21000.0 in 2021 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 9973.19% in 2021; the steepest drop was 1072.65% in 2021.
  • Rein Therapeutics' Shares Issued stood at -$55.5 million in 2021, then soared by 87.59% to -$6.9 million in 2024, then soared by 117.83% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Shares Issued are $1.2 million (Q3 2025), -$345000.0 (Q2 2025), and $712000.0 (Q1 2025).